Pomerantz LLP
Search documents
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capital One Financial Corporation – COF
Globenewswire· 2026-01-27 22:29
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capital One Financial Corporation (“Capital One” or the “Company”) (NYSE: COF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Capital One and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class ac ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sigma Lithium Corporation – SGML
Globenewswire· 2026-01-27 22:21
Core Viewpoint - Sigma Lithium Corporation is under investigation for potential securities fraud and unlawful business practices, following a series of operational and liquidity issues that have negatively impacted its stock performance [1][3]. Group 1: Company Performance and Stock Impact - On January 8, 2026, Bank of America downgraded Sigma Lithium from Neutral to Underperform due to unresolved operational and liquidity issues, leading to a stock price decline of $2.36 per share, or 15.07%, closing at $13.30 per share [3]. - Following a report on January 15, 2026, regarding the shutdown of three waste piles at Sigma Lithium's mine by Brazil's Labor Ministry due to safety concerns, the stock price fell by $4.32 per share, or 26.04%, closing at $12.27 per share on January 16, 2026 [4]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Sigma Lithium investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BlackRock TCP Capital Corp. - TCPC
Globenewswire· 2026-01-27 22:10
Core Viewpoint - BlackRock TCP Capital Corp. is under investigation for potential securities fraud and unlawful business practices following a significant decline in its net asset value due to rising nonperforming loans [1][2]. Group 1: Company Performance - On January 23, 2026, BlackRock TCP reported a 19% decline in the net asset value of its private corporate loans, attributed to a sharp increase in nonperforming loans [2]. - Following this announcement, BlackRock TCP's stock price decreased by $0.76 per share, representing a 12.97% drop, closing at $5.10 per share on January 26, 2026 [2]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of BlackRock TCP investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of T1 Energy Inc. – TE
Globenewswire· 2026-01-27 22:10
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of T1 Energy Inc. (“T1” or the “Company”) (NYSE: TE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether T1 and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On January 21, 2026, Culper Rese ...
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM
Globenewswire· 2026-01-27 18:42
Group 1 - A class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. regarding potential securities fraud or unlawful business practices by the company and its officers [1][2] - Investors have until February 23, 2026, to request to be appointed as Lead Plaintiff if they purchased Quantum securities during the Class Period [2] - The lawsuit alleges that certain financial institutions engaged in manipulative trading practices, including spoofed sell orders, to create a false impression of Quantum's stock price decline [4] Group 2 - The defendants in the lawsuit include CIBC World Markets, RBC Dominion Securities, and Royal Bank of Canada, among others, who are accused of deceiving investors into selling shares at artificially low prices [4] - Pomerantz LLP, the law firm handling the case, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [5]
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Smart Digital Group Limited of Class Action Lawsuit and Upcoming Deadlines - SDM
Globenewswire· 2026-01-27 18:41
Core Viewpoint - A class action lawsuit has been filed against Smart Digital Group Limited, alleging securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that Smart Digital and certain officers and/or directors engaged in securities fraud [2]. - Investors have until March 16, 2026, to request to be appointed as Lead Plaintiff if they purchased Smart Digital securities during the Class Period [2]. Group 2: Stock Price and SEC Actions - On September 26, 2025, Smart Digital's stock price dropped 86.4% to close at $1.85 per share after a trading halt due to volatility [4]. - The SEC suspended trading in Smart Digital securities from September 29, 2025, to October 10, 2025, due to potential manipulation linked to social media recommendations [4]. - Following the SEC suspension, NASDAQ also suspended trading in Smart Digital securities pending further information [4]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [5].
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in F5, Inc. of Class Action Lawsuit and Upcoming Deadlines - FFIV
Globenewswire· 2026-01-27 18:37
Core Viewpoint - A class action lawsuit has been filed against F5, Inc. concerning allegations of securities fraud and unlawful business practices related to a significant security breach and its impact on the company's financial performance [2][4]. Group 1: Lawsuit Details - The class action lawsuit involves F5 and certain officers and/or directors, with investors encouraged to contact Pomerantz LLP for participation [1][2]. - Investors who purchased F5 securities during the Class Period have until February 17, 2026, to request appointment as Lead Plaintiff [2]. Group 2: Security Breach Impact - On October 15, 2025, F5 disclosed a "long-term, persistent" breach affecting its BIG-IP product development and engineering management platforms, including the source code [4]. - Following the breach announcement, F5's stock price dropped by $47.82, or 13.93%, closing at $295.35 on October 16, 2025 [4]. - On October 27, 2025, F5 reported fiscal year 2025 results that significantly missed market growth expectations for fiscal year 2026, attributing this to the security breach [5]. - The subsequent announcement led to a further decline in F5's stock price by $30.76, or 10.31%, closing at $258.76 on October 28, 2025 [6].
*CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
Globenewswire· 2026-01-27 18:33
Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Inovio Pharmaceuticals and its executives [1] Group 1: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107, a treatment for recurrent respiratory papillomatosis, but did not find sufficient information for accelerated approval [3] - Inovio announced it will not pursue approval under the standard review timeline and plans to meet with the FDA to discuss options for accelerated approval [3] Group 2: Market Reaction - Following the FDA announcement, Inovio's stock price dropped by $0.56 per share, a decline of 24.45%, closing at $1.73 per share on December 29, 2025 [4]
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BigBear.ai Holdings, Inc. - BBAI
Globenewswire· 2026-01-27 18:17
Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving BigBear.ai Holdings, Inc. and its officers or directors [1] Group 1: Company Performance - Cantor analysts downgraded BigBear from Overweight to Neutral on January 7, 2026, citing a 20% year-over-year revenue decline [3] - The downgrade was attributed to elevated execution risk due to reliance on inconsistent government contracts, leading to ongoing operating losses and margin pressure [3] - BigBear reported an adjusted EBITDA of ($9.4 million) in Q3 2025 and an operating margin of (66.0%) [3] Group 2: Market Reaction - Following the downgrade by Cantor, BigBear's stock price decreased by $0.42 per share, or 6.55%, closing at $5.99 per share on January 7, 2026 [3]
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AST SpaceMobile, Inc. - ASTS
Globenewswire· 2026-01-27 18:12
Core Viewpoint - Pomerantz Law Firm is investigating claims on behalf of investors of AST SpaceMobile, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [2]. Group 1: Investigation Details - The investigation focuses on whether AST and certain officers and/or directors have engaged in securities fraud or other unlawful business practices [2]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Market Reaction - On January 7, 2026, Scotiabank downgraded AST to Sell, citing significant competition from SpaceX's Starlink, slow customer adoption, and delays in launching AST's satellites [4]. - Following the downgrade, AST's stock price fell by $11.76 per share, or 12.06%, closing at $85.73 per share on the same day [4].